Crystalluria and urinary tract abnormalities associated with indinavir.
about
Proteinuria in paediatric patients with human immunodeficiency virus infectionTreatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable by rehydrationImproving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteersHyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.Urinary NO3 excretion and renal failure in indinavir-treated patients.Symptomatic crystalluria associated with indinavir.Practical issues regarding the use of antiretroviral therapy for HIV infectionMagnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.Antiretroviral drugs in pediatrics.The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome.Nephrotoxicity related to new therapeutic compounds.Principles and practice of HIV-protease inhibitor pharmacoenhancement.Structured Treatment Interruption: Approaches and Risks.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.The role of protease inhibitor therapy in children with HIV infection.Nephrotoxicity of HAARTApproach to the Adult Kidney Stone FormerDrug-induced nephropathy: an update.The 6R's of drug induced nephrotoxicityAntiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.Kidney disease in children and adolescents with perinatal HIV-1 infection.Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.A review of the toxicity of HIV medications.Ritonavir-boosted protease inhibitors in HIV therapy.Renal toxicity associated with antiretroviral therapy.Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge.HIV medication-based urolithiasis.Single-dose pharmacokinetics of indinavir and the effect of food.[Diagnosis and treatment of nephrolithiasis. What is established?].Crystalluria in HIV/AIDS patients on highly active anti-retroviral therapy in the Kumasi metropolis; a cross sectional study.High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.Acute interstitial nephritis secondary to the administration of indinavir.Ceftriaxone-associated nephrolithiasis.Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings.
P2860
Q27009315-E615442F-32C4-46F8-B667-DABFD73C3C06Q28373548-6DEED245-6973-4457-A161-9847BDAF3BD2Q31062643-F9A2D55C-A131-4FE8-B47D-16321D9AF140Q33700538-590189BF-6314-4F3E-98D8-E0E01DEC6A1AQ33941936-5C0A99F5-1539-4209-8BEB-A7D3E6DB1A49Q33952995-0F68F66C-439B-4A24-A35F-FDBECAC9F4A7Q33998505-7B0151D0-A47A-47AE-AA07-0BBA924EBA14Q34122511-EB820878-E750-436E-AB3C-9118458F1A92Q34187889-D452FA8A-F1E8-44E4-9E69-93ED3BE54153Q34332166-4722FE5E-71A6-4C41-8B2B-1C077C5C7B09Q34344415-B824E565-C532-42A2-B887-5E9EDB6C9429Q34419035-068CF29E-865B-4D46-8F68-357ACDB93C7EQ34426673-5A2843AF-7668-402A-85B2-1B3F99188E54Q34459378-C5AC20D7-B12E-4C6A-A913-96876159359BQ34583760-74FB21E7-0BCA-4E71-9356-C7A6455EB66AQ34686870-CBB9A75D-5038-4382-8048-FCA4F7E068ABQ34736194-0CC13219-C177-439A-9C3D-9A4BB108C06CQ34755325-437DC7D4-4D17-44F8-8E42-A0128030A9EAQ34783374-C621E210-5D6B-4E1B-9368-45747E349E6DQ35167944-BAC040A9-72C3-4D36-9797-4B1354E7A05FQ35990584-DEB78CBC-0A99-4F5D-805E-D23AB91AB332Q36191026-34734300-E52F-48A3-866C-01FF47AEB06AQ36333140-F2F2A27E-9101-4B56-B52C-AB460DA8C2C5Q36407276-21CD6C8A-EFC5-4015-A381-C7106ABC228BQ36808038-D6F4D863-5303-4D8A-9381-AAD37B4334C7Q36835807-6B884FAC-FE59-4E01-B2FB-FA93CE5E2160Q36942310-65F183EB-F0C3-4C97-AFE7-A97A3F2F9119Q37154741-8388FA90-8323-4C8A-89B5-B0CBA3EF9196Q37633495-9E4A74AE-EDCA-4795-9CAB-6ABF3A73ABD1Q37866319-8E581294-010F-470C-AD3B-CDF4E88C48A3Q38031028-7B2B947D-D8D3-40DE-B88C-0FDC427B3083Q38219884-C697A3F8-7AF1-4184-A08D-616B78E4D8F3Q38411142-0DE9D91E-0E30-4750-A8AB-7A43FF5561E4Q39556676-BFB78C84-3D83-4716-A59D-5A3F53E285E7Q40132732-12D1784A-898F-4A4E-86B5-16254BD446E1Q41583156-06F8BAB6-BA2A-4ED5-AD2B-6F028A3EE20BQ42266062-EC385974-C6EB-4226-9AED-7B5600053E84Q42540802-0321129A-3AB5-4055-A62C-C82FAD87BB8BQ43506962-0454C100-18A6-4AB4-9C16-651ADCBEBC11Q43933903-7DEFDDB1-A980-41C1-841B-E237D83567F9
P2860
Crystalluria and urinary tract abnormalities associated with indinavir.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Crystalluria and urinary tract abnormalities associated with indinavir.
@en
Crystalluria and urinary tract abnormalities associated with indinavir.
@nl
type
label
Crystalluria and urinary tract abnormalities associated with indinavir.
@en
Crystalluria and urinary tract abnormalities associated with indinavir.
@nl
prefLabel
Crystalluria and urinary tract abnormalities associated with indinavir.
@en
Crystalluria and urinary tract abnormalities associated with indinavir.
@nl
P2093
P1476
Crystalluria and urinary tract abnormalities associated with indinavir.
@en
P2093
Feuerstein IM
Pannell LK
P304
P356
10.7326/0003-4819-127-2-199707150-00004
P407
P577
1997-07-01T00:00:00Z